Azim Premji, the chairman of Wipro Limited, is one of the investors in Moderna, a US firm which has recently developed a coronavirus vaccine which has shown good results in phase 1 of its vaccine testing in the United States.
Founded in 2010, Moderna believes mRNA could be used to create a new category of medicines with significant potential to improve the lives of patients. Moderna is involved in pioneering a new class of medicines made of messenger RNA, or mRNA. The firm believes that the potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured.
The firm is now working on mRNA-1273, a vaccine candidate against the novel coronavirus. According to the firm’s website, it has started preparing for rapid acceleration of its manufacturing capabilities that could allow for the future manufacture of millions of doses should mRNA-1273 prove to be safe and of expected benefit.
